N-Acetylcysteine’s Renoprotective Effect in Cardiac Surgery: A Systematic Review and Meta-Analysis

• Published in: Annals of Thoracic and Cardiovascular Surgery Vol. 28; no. 2; pp. 138 - 145
• Main Authors: Tan, Ying Kiat, Luo, HaiDong, Kang, Giap Swee, Teoh, Kristine LK, Kofidis, Theo
• Format: Journal Article
• Language: English
• Published: Japan The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery 2022
• Subjects: Acetylcysteine - adverse effects; acute kidney injury; Acute Kidney Injury - diagnosis; Acute Kidney Injury - epidemiology; Acute Kidney Injury - etiology; Adult; cardiac surgery; Cardiac Surgical Procedures - adverse effects; Female; Humans; Male; N-acetylcysteine; Odds Ratio; Original; Treatment Outcome; cardiac surgery; acute kidney injury; N-acetylcysteine
• ISSN: 1341-1098; 2186-1005
• DOI: 10.5761/atcs.oa.21-00132

Objective: To examine N-acetylcysteine’s (NAC’s) renoprotective effect in adult cardiac surgeryMethods: PubMed, Ovid Medline, and Embase were searched for randomized controlled trials published between January 1990 and May 2021 that investigated the effect of NAC in preventing acute kidney injury (AKI) in patients undergoing cardiac surgery. The inclusion criterion was studies that assessed the effect of NAC in comparison to placebo by measuring the incidence of AKI.Results: Overall meta-analytic estimates of all 10 included trials showed that NAC did not have a significant effect (odds ratio [OR]: 0.84, 95% confidence interval [CI]: 0.64–1.10) on AKI. Further subgroup analysis did not show a significant benefit of NAC in preventing AKI.Conclusion: This meta-analysis suggests that NAC does not have a significant effect in reducing the incidence of AKI. However, there is notable heterogeneity among the included studies that could possibly account for the non-significant effect observed. It is worth noting that only one trial administered NAC high dosages perioperatively, and it is the only included trial to show a significant benefit in reducing the incidence of AKI (OR: 0.30, 95% CI: 0.11–0.81). Further studies on this dosage and duration of administration should be conducted to best elucidate the effect of administering NAC.